These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 29179585)

  • 1. Immune-based strategies for mood disorders: facts and challenges.
    Colpo GD; Leboyer M; Dantzer R; Trivedi MH; Teixeira AL
    Expert Rev Neurother; 2018 Feb; 18(2):139-152. PubMed ID: 29179585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the immune system in the treatment of bipolar disorder.
    Rosenblat JD
    Psychopharmacology (Berl); 2019 Oct; 236(10):2909-2921. PubMed ID: 30756134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response to stress induction as a predictor of cognitive-behavioral therapy outcomes in adolescent mood disorders: A pilot study.
    Pearlstein JG; Staudenmaier PJ; West AE; Geraghty S; Cosgrove VE
    J Psychiatr Res; 2020 Jan; 120():56-63. PubMed ID: 31634750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
    Bond DJ; Hadjipavlou G; Lam RW; McIntyre RS; Beaulieu S; Schaffer A; Weiss M;
    Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.
    Rosenblat JD; Kakar R; Berk M; Kessing LV; Vinberg M; Baune BT; Mansur RB; Brietzke E; Goldstein BI; McIntyre RS
    Bipolar Disord; 2016 Mar; 18(2):89-101. PubMed ID: 26990051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.
    Schaffer A; McIntosh D; Goldstein BI; Rector NA; McIntyre RS; Beaulieu S; Swinson R; Yatham LN;
    Ann Clin Psychiatry; 2012 Feb; 24(1):6-22. PubMed ID: 22303519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitigation of Inflammation-Induced Mood Dysregulation by Long-Chain Omega-3 Fatty Acids.
    McNamara RK
    J Am Coll Nutr; 2015; 34 Suppl 1(0 1):48-55. PubMed ID: 26400435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
    McNamara RK; Lotrich FE
    Expert Rev Neurother; 2012 Sep; 12(9):1143-61. PubMed ID: 23039393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder.
    Khairova RA; Machado-Vieira R; Du J; Manji HK
    Int J Neuropsychopharmacol; 2009 May; 12(4):561-78. PubMed ID: 19224657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Promise and Limitations of Anti-Inflammatory Agents for the Treatment of Major Depressive Disorder.
    Raison CL
    Curr Top Behav Neurosci; 2017; 31():287-302. PubMed ID: 27278642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics.
    Vazquez GH; Camino S; Tondo L; Baldessarini RJ
    CNS Neurol Disord Drug Targets; 2017; 16(8):858-869. PubMed ID: 28758582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of anti-inflammatory treatment interventions on depression in individuals with major depressive disorder and high levels of inflammation: A systematic review of randomized clinical trials.
    Allison DJ; Sharma B; Timmons BW
    Physiol Behav; 2019 Aug; 207():104-112. PubMed ID: 31078670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA therapeutics for mood disorders: current evidence toward clinical trials.
    Le Marois M; Tzavara E; Ibrahim EC; Blin O; Belzeaux R
    Expert Opin Investig Drugs; 2021 Jul; 30(7):721-736. PubMed ID: 33966550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of neuro-immunological factors in the pathophysiology of mood disorders.
    Bhattacharya A; Derecki NC; Lovenberg TW; Drevets WC
    Psychopharmacology (Berl); 2016 May; 233(9):1623-36. PubMed ID: 26803500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012.
    Kanba S; Kato T; Terao T; Yamada K;
    Psychiatry Clin Neurosci; 2013 Jul; 67(5):285-300. PubMed ID: 23773266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease.
    Zuzarte P; Duong A; Figueira ML; Costa-Vitali A; Scola G
    Curr Drug Metab; 2018; 19(8):674-687. PubMed ID: 29512447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Drugs for Mood Disorders.
    Peedicayil J; Kumar A
    Prog Mol Biol Transl Sci; 2018; 157():151-174. PubMed ID: 29933949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins: Neurobiological underpinnings and mechanisms in mood disorders.
    Walker AJ; Kim Y; Borissiouk I; Rehder R; Dodd S; Morris G; Nierenberg AA; Maes M; Fernandes BS; Dean OM; Williams LJ; Eyre HA; Kim SW; Zoungas S; Carvalho AF; Berk M
    Neurosci Biobehav Rev; 2021 Sep; 128():693-708. PubMed ID: 34265321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the gut microbiome and mood disorders.
    Mörkl S; Butler MI; Lackner S
    Curr Opin Psychiatry; 2023 Jan; 36(1):1-7. PubMed ID: 36131643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis.
    Husain MI; Strawbridge R; Stokes PR; Young AH
    J Psychopharmacol; 2017 Sep; 31(9):1137-1148. PubMed ID: 28858537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.